RxDoctor Payments Data

Coleen Palileo, MD

Ophthalmology · Bellevue, WANPI 1427411446

Payments from drug & device makers

$2,662in general payments, 2019–2025

Across 46 payments — averaging $57.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Amgen$656
  • Topcon Healthcare, Inc.$163
  • Bausch & Lomb Americas Inc.$148
  • Sun Pharmaceutical Industries Inc.$86
  • Mallinckrodt Enterprises LLC$75
  • plus $143 from 5 others

What the payments were for

  • Food & beverage$2,58997%
  • Education$733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,662 in reported general payments places this provider in the 70th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$271,520
Medicare patients
611
Services billed
2,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$9,161
Cyclosporine11$5,957
ProlensaBromfenac Sodium12$4,313
Travoprost14$2,743
Loteprednol Etabonate17$2,287
Latanoprost202$2,056
Prednisolone Acetate36$1,716
Tobramycin-DexamethasoneTobramycin/Dexamethasone39$1,546
ErythromycinErythromycin Base115$1,235
Brimonidine Tartrate33$871
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat64$836
Timolol Maleate47$587
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha53$584
Dorzolamide Hcl17$368
Doxycycline Hyclate12$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$15$9,16113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →